Manoj Chevli
Overview
Explore the profile of Manoj Chevli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
4
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Passamonti F, Korgaonkar S, Parikh R, Chevli M, Yucel A, Rombi J, et al.
Future Oncol
. 2025 Jan;
21(5):579-591.
PMID: 39865562
Aim: Assess real-world fedratinib (FEDR) treatment patterns and clinical outcomes in patients with primary or secondary myelofibrosis following discontinuation of ruxolitinib (RUX). Patients & Methods: This study was a retrospective,...
2.
Mims A, Xie Z, Potluri R, Rotter D, Chevli M, Prebet T, et al.
Leuk Lymphoma
. 2024 Nov;
66(3):479-487.
PMID: 39606887
Oral azacitidine (Oral-AZA) is recommended as maintenance therapy for patients with newly diagnosed acute myeloid leukemia (ND AML) achieving remission with intensive chemotherapy (IC) but not transplant candidates; venetoclax plus...
3.
Borate U, Seiter K, Potluri R, Mazumder D, Chevli M, Prebet T, et al.
Adv Ther
. 2024 Sep;
41(11):4049-4064.
PMID: 39240504
Introduction: The substantial economic burden of acute myeloid leukemia (AML) could be reduced with post-remission maintenance therapies that delay relapse. Real-world healthcare resource utilization (HCRU) data and costs among patients...
4.
Passamonti F, Lou Y, Chevli M, Abraham P
Future Oncol
. 2023 Nov;
20(17):1165-1174.
PMID: 37991002
Fedratinib is an oral selective JAK2 inhibitor approved in the USA for the treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis (MF). This observational study assessed...
5.
Martin A, Ferri Grazzi E, Mighiu C, Chevli M, Shah F, Maher L, et al.
Eur J Health Econ
. 2022 Mar;
24(1):27-38.
PMID: 35347553
Background: Beta-thalassemia (BT) is an inherited blood disorder characterized by reduced levels of functional hemoglobin resulting in phenotypes ranging from clinically asymptomatic to severely anemic. Patients with BT may require...
6.
Nicholas R, Heaven M, Middleton R, Chevli M, Pulikottil-Jacob R, Jones K, et al.
Mult Scler J Exp Transl Clin
. 2020 Feb;
6(1):2055217320901727.
PMID: 32030197
Objectives: To investigate through survey and data linkage, healthcare resource use and costs (except drugs), including who bears the cost, of multiple sclerosis in the United Kingdom by disease severity...